{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreif6ip75etgpaw6ko6fpft4kgsmfib67wcn5o7te4ahzqcmyiroovy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmrskszoop52"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia55wloryyvpcpcebpx633tclwlaxa6yb22vn77t7xmm5vxz4busu"
    },
    "mimeType": "image/jpeg",
    "size": 215706
  },
  "path": "/news/2026-05-vitamin-d-analog-pancreatic-cancer.html",
  "publishedAt": "2026-05-26T15:52:42.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.",
  "title": "Vitamin D analog shuts down pancreatic cancer's shield in a clinical trial"
}